A synthetic biology roadmap for sustainable production of the plant-originated anti-cancer drug paclitaxel
Trends in Biotechnology · 2026
DOI: 10.1016/j.tibtech.2025.11.013 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Trends in Biotechnology, 2026. Verfasst von Chun-Lin Tan und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Southwestern Chinese Medicine Resources, Innovative Institute of Chinese Medicine and Pharmacy, Chengdu University of Traditi…. Hauptthemen laut MEDLINE: Paclitaxel, Synthetic Biology, Metabolic Engineering, Antineoplastic Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 99 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Sichuan Provincial Postdoctoral Science Foundation.
Abstract (Originalsprache)
Paclitaxel, a clinically potent anticancer drug derived from Taxus species, faces persistent challenges in sustainable supply. Synthetic biology presents substantial opportunities for its de novo production, particularly with recent breakthroughs in elucidating its intricate biosynthetic pathways. However, its heterologous biosynthesis is significantly constrained by key bottlenecks, including pathway complexity, poor P450 expression, and inefficient metabolic flux. In this study, we explore how synthetic biology facilitates pathway decoding and reconstruction and propose strategies involving nonclassical chassis such as plant-associated cyanobacteria and filamentous fungi to enhance P450 compatibility. We also present a pragmatic framework for the rational application of state-of-the-art tools, including cell-free systems, synthetic microbial consortia, hybrid chemoenzymatic synthesis, and machine learning, to sustainably produce paclitaxel and other natural products.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Southwestern Chinese Medicine Resources, Innovative Institute of Chinese Medicine and Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, PR China.
- Max Planck Institute for Chemical Ecology, Jena 07745, Germany.
- State Key Laboratory of Southwestern Chinese Medicine Resources, Innovative Institute of Chinese Medicine and Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, PR China; State Key Laboratory…
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Sichuan Provincial Postdoctoral Science Foundation
- Natural Science Foundation of Sichuan Province
- China Postdoctoral Science Foundation
Zitieren
APA
Tan, C. L., Yu, X., Feng, H. C., Gershenzon, J., Liu, Y., & Li, S. H. (2026). A synthetic biology roadmap for sustainable production of the plant-originated anti-cancer drug paclitaxel. Trends in Biotechnology. https://doi.org/10.1016/j.tibtech.2025.11.013
Vancouver
Tan CL, Yu X, Feng HC, Gershenzon J, Liu Y, Li SH. A synthetic biology roadmap for sustainable production of the plant-originated anti-cancer drug paclitaxel. Trends in Biotechnology. 2026. doi:10.1016/j.tibtech.2025.11.013
BibTeX
@article{Tan2026,
author = {Tan, Chun-Lin and Yu, Xin and Feng, Hui-Cheng and Gershenzon, Jonathan and Liu, Yan and Li, Sheng-Hong},
title = {A synthetic biology roadmap for sustainable production of the plant-originated anti-cancer drug paclitaxel},
journal = {Trends in Biotechnology},
year = {2026},
doi = {10.1016/j.tibtech.2025.11.013}
}
EUVIMED